Search research articles
Contact Us
Filters
Showing results (1401-1410 of 1,592) with videos related to
Page
of 160
Sort By:
Nature
|
May 20, 2026
Mitochondrial L-2-hydroxyglutarate is a physiological signalling metabolite
Ram P Chakrabarty, Jonathan G Van Vranken, Yuki Aoi, et al.
Nature
|
February 17, 2000
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
A A Alizadeh, M B Eisen, R E Davis, et al.
MMWR. Morbidity and Mortality Weekly Report
|
June 15, 2023
Genomic Surveillance for SARS-CoV-2 Variants: Circulation of Omicron Lineages - United States, January 2022-May 2023
Kevin C Ma, Philip Shirk, Anastasia S Lambrou, et al.
Nature
|
June 4, 2025
Integrated photonic source of Gottesman-Kitaev-Preskill qubits
M V Larsen, J E Bourassa, S Kocsis, et al.
Medrxiv : the Preprint Server for Health Sciences
|
February 9, 2026
Genomic surveillance of human metapneumovirus in the United States, 2010 - 2025
Emily E Bendall, William J Fitzsimmons, Weronika Damek Valvano, et al.
Cancer Discovery
|
April 2, 2024
Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors
Federica Pecci, Seshiru Nakazawa, Biagio Ricciuti, et al.
The New England Journal of Medicine
|
February 22, 2018
Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children
Alexander Drilon, Theodore W Laetsch, Shivaani Kummar, et al.
Journal of the National Cancer Institute
|
April 5, 2017
Co-activation of STAT3 and YES-Associated Protein 1 (YAP1) Pathway in EGFR-Mutant NSCLC
Imane Chaib, Niki Karachaliou, Sara Pilotto, et al.
The Journal of Infectious Diseases
|
May 6, 2026
Genomic surveillance of human metapneumovirus in the United States, 2010-2025
Emily E Bendall, William J Fitzsimmons, Weronika Damek Valvano, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 19, 2023
Neratinib + fulvestrant + trastuzumab for HR-positive, HER2-negative, HER2-mutant metastatic breast cancer: outcomes and biomarker analysis from the SUMMIT trial
K Jhaveri, L D Eli, H Wildiers, et al.
Page
of 160
Search research articles
Search
Showing results (1401-1410 of 1,592) with videos related to
Sort By:
Page
of 160
Nature
|
May 20, 2026
Mitochondrial L-2-hydroxyglutarate is a physiological signalling metabolite
Ram P Chakrabarty, Jonathan G Van Vranken, Yuki Aoi, et al.
Nature
|
February 17, 2000
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
A A Alizadeh, M B Eisen, R E Davis, et al.
MMWR. Morbidity and Mortality Weekly Report
|
June 15, 2023
Genomic Surveillance for SARS-CoV-2 Variants: Circulation of Omicron Lineages - United States, January 2022-May 2023
Kevin C Ma, Philip Shirk, Anastasia S Lambrou, et al.
Nature
|
June 4, 2025
Integrated photonic source of Gottesman-Kitaev-Preskill qubits
M V Larsen, J E Bourassa, S Kocsis, et al.
Medrxiv : the Preprint Server for Health Sciences
|
February 9, 2026
Genomic surveillance of human metapneumovirus in the United States, 2010 - 2025
Emily E Bendall, William J Fitzsimmons, Weronika Damek Valvano, et al.
Cancer Discovery
|
April 2, 2024
Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors
Federica Pecci, Seshiru Nakazawa, Biagio Ricciuti, et al.
The New England Journal of Medicine
|
February 22, 2018
Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children
Alexander Drilon, Theodore W Laetsch, Shivaani Kummar, et al.
Journal of the National Cancer Institute
|
April 5, 2017
Co-activation of STAT3 and YES-Associated Protein 1 (YAP1) Pathway in EGFR-Mutant NSCLC
Imane Chaib, Niki Karachaliou, Sara Pilotto, et al.
The Journal of Infectious Diseases
|
May 6, 2026
Genomic surveillance of human metapneumovirus in the United States, 2010-2025
Emily E Bendall, William J Fitzsimmons, Weronika Damek Valvano, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 19, 2023
Neratinib + fulvestrant + trastuzumab for HR-positive, HER2-negative, HER2-mutant metastatic breast cancer: outcomes and biomarker analysis from the SUMMIT trial
K Jhaveri, L D Eli, H Wildiers, et al.
Page
of 160